Join to access to all OVN content. Join for Free
Best Practices and Creative Ways to Gain KOL Access During COVID-19
Provide 5 SEO Keywords separated by commas

Best Practices and Creative Ways to Gain KOL Access During COVID-19


Share This Article


Summary

In this episode, Tom Caravela speaks with Jason Demuth about his journey from retail pharmacy to the pharmaceutical industry. Jason shares his experiences engaging Key Opinion Leaders (KOLs) during COVID, emphasizing the strategic use of social media and email communication. The discussion explores the future of KOL access and offers strategies for aspiring MSLs. Jason compares roles in big pharma versus small pharma and highlights the importance of networking and recruiters in advancing MSL careers. The episode concludes with Jason's final thoughts and advice, alongside a call for listener engagement.

My guest today is Jason Demuth, Director, Medical Science Liaison at Strongbridge Bio shares creative ways to reach and access KOLs during COVID-19. 

In this episode we discuss:

  • Jason’s background
  • His journey and getting his first MSL role
  • Creative ideas and ways to access KOLs
  • His perspective on LinkedIn and Facebook for KOL engagement
  • Email interaction with KOLs
  • What is the future going to look like in terms of access in Jason’s perspective
  • His advice for new MSLs or those breaking into the role
  • Jason’s  advice for MSLs and/or MSL Leaders as we look to the future

Click for Source
Provide 5 SEO Keywords separated by commas

Related Topics

Meet Our Innovation Partners

Loading partners...

You May Also Like

Article
Does biomarker use in oncology improve clinical trial failure risk? A large-scale analysis
OVN Avatar Jayson L. Parker, Sebnem S. Kuzulugil, Kirill Pereverzev, Stephen Mac, Gilberto Lopes, Zain Shah, Ashini Weerasinghe, Daniel Rubinger, Adam Falconi, Ayse Bener, Bora Caglayan, Rohan Tangri, Nicholas Mitsakakis

Does biomarker use in oncology improve clinical trial failure risk? A large-scale analysis

Article
Assessment of Coverage in England of Cancer Drugs Qualifying for US Food and Drug Administration Accelerated Approval
OVN Avatar Avi Cherla, MSc; Huseyin Naci, MHS, PhD; Aaron S. Kesselheim, MD, JD, MPH; Bishal Gyawali, MD, PhD; Elias Mossialos, MD, PhD

Assessment of Coverage in England of Cancer Drugs Qualifying for US Food and Drug Administration Accelerated Approval

Article
Assessment of Food and Drug Administration- and European Medicines Agency-Approved Systemic Oncology Therapies and Clinically Meaningful Improvements in Quality of Life: A Systematic Review
OVN Avatar Vanessa Arciero, BS, Seanthel Delos Santos, Liza Koshy

Assessment of Food and Drug Administration- and European Medicines Agency-Approved Systemic Oncology Therapies and Clinically Meaningful Improvements in Quality of Life: A Systematic Review

Article
Clinical Educator Oncology Program Improves Adherence by 29%​
Partner Avatar iNIZIO

Clinical Educator Oncology Program Improves Adherence by 29%​

Article
New Book Unites Oncology’s Brightest Minds To Innovate Cancer Cures
OVN Avatar Forbes Books Press Release Official

New Book Unites Oncology’s Brightest Minds To Innovate Cancer Cures

Article
CheckMate-067: Raising the Bar for the Next Decade in Oncology
OVN Avatar Sarah A. Weiss, MD, and Harriet Kluger, MD

CheckMate-067: Raising the Bar for the Next Decade in Oncology

Explore OVN